ASH Data Give Millennium’s Velcade A Boost, Raise Bar For Competitors

Myeloma trial data released at the American Society of Hematology meeting promises to further lift utilization for Takeda/Millennium's proteasome inhibitor Velcade, which just passed $1 billion in sales